Title
Group Insider Policy
Human Stem Cells
Position on Human Specimen Resources (Biobanks)
Finance Report 2022
Annual Report 2022
Supplier Code of Conduct (German)
Supplier Code of Conduct (English)
Nanotechnology
Six bold actions for regulatory reform (EU)
Roche’s Position on Access to & Use of Real World Data
Roche FAQ Clinical Research
Half-Year Report 2022
Roche position on incentivising the development and appropriate use of new antibiotics
EFPIA Disclosure Code Self-Certification Scheme
Responsible Sharing of Scientifically Credible Information on the portal
Pre-Approval Access to Investigational Medicinal Products
Finance Report 2021
Annual Report 2021
Employment Policy (German)
Employment Policy (Spanish)
Employment Policy (English)
Employment Policy (Chinese)
Employment Policy (French)
Employment Policy (Italian)
Roche Group Code of Conduct - Addendum for France (French)
Roche Group Code of Conduct - Addendum for France (English)
Waste Management and Circular Economy
Energy Conservation
Prevention of Misuse of Biological Materials and Toxins for Biowarfare
Water
Half-Year Report 2021
EFPIA Disclosure Code Self-Certification Scheme
Roche Position on TRIPS and the Doha Declaration
Roche Position on Enabling Access through Collaboration
Climate Change Risk Management
Policy on Safety, Security, Health and Environmental Protection
Roche’s Approach to Tax – General Description and Principles
Roche's Position on Partnering with Patient Communities
Finance Report 2020
Annual Report 2020
Roche Position on Health Technology Assessment
Half-Year Report 2020
EFPIA Disclosure Code Self-Certification Scheme
Biodiversity
Biotechnology - Safety Health and Environmental Aspects
Clinical Research
Counterfeiting
Greenhouse gases / Climate Change
Landfills / Contaminated Soil
Personalised Healthcare
Pharmaceuticals in the Environment
Pricing
R&D for Neglected Tropical Disease
Similar Biotherapeutic Products - Biosimilars
Pollution Prevention and Reduction
Product Stewardship
Safety, Security, Health and Environmental Protection (SHE) in the supply chain
Human Rights
Human Genetic and Genomic Research
Animal Research at Roche
Roche Group Code of Conduct (Chinese)
Roche Group Code of Conduct (German)
Roche Group Code of Conduct (Spanish)
Roche Group Code of Conduct (French)
Roche Group Code of Conduct - Addendum for France (French)
Roche Group Code of Conduct (Italian)
Roche Group Code of Conduct (Portuguese - Brasil)
Roche Group Code of Conduct (Japanese)
Roche Group Code of Conduct (Portuguese)
Roche Group Code of Conduct (Russian)
Roche Group Code of Conduct (Turkish)
Roche Group Code of Conduct (English)
Roche in Brief 2019
Finance Report 2019
Annual Report 2019
Half-Year Report 2019
EFPIA Disclosure Code Self-Certification Scheme
SHE Guidelines
Roche in Brief 2018
Finance Report 2018
Annual Report 2018
Compliance
Roche illness rate and occupational illnesses
Roche accident rate
Supporting Biodiversity
Waste Management
Use of water
Emissions to water
Other emissions to air
Greenhouse Gas Emissions
Energy Consumption
Eco-balance
SHE expenditures
Materiality
Roche Directive Collaborating with Patient Groups and Patients
Intellectual Property, Fueling Innovation & Advancing Healthcare
Certificate on Roche's Sustainability Commitments, Initiatives and Performance
Employment Policy
Half-Year Report 2018
Group Business Continuity Management Policy
Working with Government Officials
Philanthropic Donations and Non-commercial Sponsorship
Organisationsreglement
Bylaws
Transport
Roche in Brief 2017
Finance Report 2017
Annual Report 2017
Roche Policy on sharing of clinical study information
EFPIA Disclosure Code Self-Certification Scheme
Benefits - Switzerland
Full Year 2016 Presentation without appendix
Finance Report 2016
Counterfeit Medicinal products
SHE Organization Chart
Behaviour in Competition
Behaviour in Competition (German)
Articles of Incorporation
Roche Specimen Repositories
Directive K18 - Annex 2 (Lighting)
Directive K1 - Annex 5 (Mental Health Protection)
Directive K1 - Occupational Health
Behaviour in Business (English)
Behaviour in Business (German)
Behaviour in Business (French)
Minutes of the 96th Annual General Meeting of the Shareholders of ROCHE HOLDING LTD
Continued Access to Investigational Medicines
Risk Management
Memberships and International CR Recommendations